SenesTech, Inc. received a formal notification from The Nasdaq Stock Market LLC on October 20, 2026, indicating that the company failed to meet the minimum bid price requirement for continued listing on the Nasdaq Capital Market. The listing qualifications staff informed the company that the closing bid price of its common stock had remained below $1.00 per share for 30 consecutive business days, a violation of Nasdaq Listing Rule 5550(a)(2). This development raises immediate questions for investors regarding the security of the ticker's status, although the notification carries no immediate effect on trading.
The stock continues to trade on the Nasdaq Capital Market under the symbol SNES. Under Nasdaq Listing Rule 5810(c)(3)(A), SenesTech is granted a 180-calendar-day compliance period to regain standing, which expires on April 19, 2027. Michael Edell, President and Chief Executive Officer of SenesTech, stated that the company takes the notification seriously and intends to utilize the compliance period to demonstrate ongoing business progress.
Supporting its case for operational momentum, Edell highlighted that preliminary third-quarter revenue reached approximately $1.1 million. He noted this figure represents the highest in the company's history, marking a 40% increase from the second quarter and a 55% increase from the third quarter of 2025. Edell expressed belief that continued execution and broader investor awareness could create opportunities for the share price to better reflect the value he sees in the business.
Long-term holder Glenbrook Capital Management publicly congratulated SenesTech on its recently announced revenue growth. Glenbrook disclosed a 38% stake in the company and proposed collaborating with directors and executives on steps to strengthen financial health and back operational goals.
SenesTech stated it intends to adopt a disciplined approach to financial management. The company is balancing the need to maintain adequate liquidity and financial resources against the costs of capital and potential dilution to existing shareholders. It continues to evaluate its financing requirements, available alternatives, and other options to regain compliance with Nasdaq listing rules.
SenesTech positions itself as a leader in rodent birth control and sustainable rodent population management. Its product portfolio includes Evolve and ContraPest fertility control solutions, alongside assessment and monitoring services designed to target reproduction and reduce rodent populations. The company serves consumer and professional markets with approaches that can be used independently or as part of an integrated pest management program.